临床试验

TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma

NCT：NCT07862647 · RECRUITING

NCT编号NCT07862647

状态RECRUITING

开始日期2026-10-29

完成时间2028-03-30

SponsorAlpheus Medical, Inc. (INDUSTRY)

First posted2026-10-07

Last updated2026-10-07

简要摘要

This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain) glioblastoma, sometimes called butterfly glioblastoma, before they complete their standard of care chemotherapy and radiation and after their standard of care chemotherapy and radiation while they are receviing their standard of care adjuvant chemotherapy.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。